标题
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
作者
关键词
-
出版物
Cancers
Volume 11, Issue 11, Pages 1654
出版商
MDPI AG
发表日期
2019-10-25
DOI
10.3390/cancers11111654
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
- (2018) Siang-Boon Koh et al. CANCER RESEARCH
- Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
- (2018) Andrea Ghelli Luserna Di Rorà et al. Journal of Hematology & Oncology
- The DNA damage response pathway in normal hematopoiesis and malignancies
- (2017) Domenico Delia et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Replication Catastrophe: When a Checkpoint Fails because of Exhaustion
- (2017) Luis Toledo et al. MOLECULAR CELL
- Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
- (2017) et al. MOLECULES
- The Intra-S Checkpoint Responses to DNA Damage
- (2017) Divya Iyer et al. Genes
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation
- (2016) Valentina Restelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage
- (2016) Ansar Karimian et al. DNA REPAIR
- Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
- (2016) Roberta Visconti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy
- (2016) Rohith Srivas et al. MOLECULAR CELL
- Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
- (2016) Andrea Ghelli Luserna Di Rorà et al. Oncotarget
- Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
- (2016) Sissel Hauge et al. Oncotarget
- Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
- (2016) Kumar Sanjiv et al. Cell Reports
- Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
- (2015) Gry Irene Magnussen et al. BMC CANCER
- In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
- (2015) Ilaria Iacobucci et al. Journal of Hematology & Oncology
- LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
- (2015) C. King et al. MOLECULAR CANCER THERAPEUTICS
- Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
- (2015) Priyanka Saini et al. Oncotarget
- Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
- (2015) Rosaria Chilà et al. Oncotarget
- TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis
- (2014) A. Stengel et al. BLOOD
- Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very highTP53mutation frequency of 93%
- (2014) Verena Mühlbacher et al. GENES CHROMOSOMES & CANCER
- Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells
- (2014) Lucy Swift et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
- (2014) Wenxiu Qi et al. Journal of Hematology & Oncology
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
- (2013) L. Chaudhuri et al. HAEMATOLOGICA
- The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis
- (2012) Tao Shen et al. Anti-Cancer Agents in Medicinal Chemistry
- Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
- (2012) Amy D Guertin et al. Cancer Cell International
- Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
- (2012) M. R. Russell et al. CANCER RESEARCH
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Claspin and Chk1 regulate replication fork stability by different mechanisms
- (2011) Jennifer Scorah et al. CELL CYCLE
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
- (2011) Raquel Domínguez-Kelly et al. JOURNAL OF CELL BIOLOGY
- Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia
- (2011) Jana Hof et al. JOURNAL OF CLINICAL ONCOLOGY
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
- (2011) C. S. Sorensen et al. NUCLEIC ACIDS RESEARCH
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
- (2010) C. Oberle et al. CURRENT GENOMICS
- Dual Regulation of Cdc25A by Chk1 and p53-ATF3 in DNA Replication Checkpoint Control
- (2008) Anastasia R. Demidova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN
- (2008) S. A. Martin et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More